Research Signal – Source date 2025-09-25
Living longer is not the same as living more years in good health. Healthspan means the period of life lived without chronic disease and disability, with function, resilience and independence preserved for as long as possible. That distinction matters because proposed anti-aging drugs are often discussed as though they were competing ways to extend life, even though they may act on different biological processes and have been tested against very different outcomes.
A narrative review published on September 25, 2025, examines five broad approaches to pharmacologically targeting aging biology: senolytics, senomorphics, NAD+ precursors, mTOR inhibitors and metabolic modifiers such as metformin. It connects these candidates with the hallmarks of aging, then compares animal findings, observational human evidence and selected clinical studies. The useful question for a reader is not which compound wins a longevity league table. It is what each strategy is intended to change, what people actually experienced in the studies discussed, and whether those changes could eventually support safe, durable prevention.
The outcome worth watching is healthspan
The review places these therapies in the context of rising multimorbidity, polypharmacy and functional decline among older adults. Age-related diseases account for a large share of disability and healthcare use, while healthy life expectancy has not kept pace with gains in total life expectancy. A treatment that delayed several diseases together could therefore matter even if it never increased maximum lifespan. The practical prize would be more time with mobility, cognitive function and independence intact, and less time managing overlapping illnesses.
That is a much higher bar than changing a molecular measurement. A drug may affect inflammation, nutrient sensing, vascular function or a circulating metabolite without yet showing that people remain independent for longer. The review repeatedly places mechanisms and surrogate outcomes beside the harder translational questions: whether an intervention produces a meaningful functional benefit, how long that benefit lasts, and whether the treatment is safe enough for people who are not seeking care for one particular disease.
Senescent cells can be removed or quieted
Cellular senescence is a stress-induced state in which a cell stops dividing. It can arise after factors such as telomere shortening, genotoxic stress or mitochondrial malfunction. Senescence can be protective: stopping damaged cells from proliferating may help suppress malignancy, and senescent cells can participate in tissue repair and wound healing. The problem is that senescent cells can also release a mixture of cytokines, chemokines, growth factors and proteases known as the senescence-associated secretory phenotype, or SASP. Over time, these signals may disturb nearby tissue and contribute to chronic inflammation and fibrosis.
Senolytics are designed to eliminate selected senescent cells. The review discusses dasatinib, quercetin and fisetin in this category, with much of the strongest evidence coming from animal models. Senomorphics pursue a different aim. They suppress or reprogram the SASP while leaving the senescent cell in place, potentially reducing harmful signals without removing a cell that still has a useful role in repair or tumor suppression.
The difference is more than a vocabulary choice. Senescent cells are heterogeneous, so a compound that removes one population may miss another or affect healthy cells. The review notes concerns including transient cytopenias with dasatinib and possible liver toxicity with high-dose flavonoids. Intermittent dosing is being considered as a way to limit exposure, but the appropriate schedule remains a research question. The safest intervention may also depend on the tissue involved: clearing cells from one setting could have a different balance of risks and benefits from changing their secretions in skin, lung or cardiovascular tissue.
Metabolism offers different levers
The other major strategies act at different points in cellular maintenance and energy handling. Rapamycin inhibits mTOR, a nutrient- and growth-sensing hub that helps regulate cell growth, protein and lipid synthesis, mitochondrial activity and autophagy. The review describes chronic mTORC1 overactivation as a feature of aging biology because it can favor growth and production over maintenance and stress resistance. Rapamycin and related drugs are therefore being studied as ways to alter that balance.
Metformin works through a different metabolic route, including activation of AMP-activated protein kinase and improved insulin sensitivity. NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide supply intermediates used to replenish NAD+, a molecule involved in cellular redox metabolism and in the activity of several enzymes linked with mitochondrial function, genomic integrity and inflammatory signaling. Aging is associated with lower NAD+ availability in multiple tissues, but restoring a molecule or pathway is not the same as proving that every tissue will respond in a durable or beneficial way.
These approaches may overlap in the broad territory of cellular maintenance, yet they are not interchangeable treatments. Rapamycin changes nutrient-sensing through mTOR. Metformin changes metabolic signaling. NAD+ precursors provide material for a central metabolic cofactor. Their mechanisms, doses, tissue effects and safety constraints can differ substantially. The fact that combinations are being considered does not make them validated anti-aging regimens; combining interventions could also combine their risks.
Human findings have measured unlike outcomes
The human observations summarized in the review illustrate why the candidates cannot be ranked by a single measure of healthy aging. Metformin has a long record in diabetes care, and retrospective cohorts of people with type 2 diabetes taking metformin showed lower rates of some outcomes, including cancer, cardiovascular disease, cognitive impairment and all-cause death, compared with relevant comparison groups. Those associations are important enough to motivate further study, but the review also identifies confounding as a limitation. People who receive one treatment may differ from comparison groups in health, care, behavior or disease management in ways that affect the result.
Smaller interventional studies in people without diabetes have examined measures such as vascular function, metabolic flexibility and inflammatory profiles. Those outcomes can help show that a drug is biologically active, but they are not equivalent to a demonstrated extension of healthspan. A change in a risk-related measure is one piece of evidence, not a finished account of what happens to function over many years.
The mTOR evidence has a different shape. In a randomized trial involving older adults, short-term everolimus improved responses to an influenza vaccine and reduced circulating pro-inflammatory cytokines. That finding makes immune resilience a plausible area for investigation, but it does not turn vaccine response into a general measure of longer independent living. The review also describes ongoing interest in rapamycin for immune, cardiac and skin-related aging outcomes, alongside efforts to refine exposure and reduce metabolic consequences.
NAD+ precursor studies have mostly established metabolic engagement and short-term biological effects. Randomized studies of nicotinamide riboside increased circulating NAD+ and reported modest improvements in blood pressure and arterial stiffness in middle-aged and older adults. A placebo-controlled study of nicotinamide mononucleotide reported improved insulin sensitivity in postmenopausal women with prediabetes. These populations and endpoints are not the same as those in the metformin or everolimus studies, so their results cannot be combined into a common score.
Senolytics were earlier in human translation within the review’s account. Small pilot studies in selected age-related illnesses explored changes such as senescent-cell burden and physical function, but the evidence remained limited in scale. The overall picture is a set of early, uneven signals: some associations, some controlled measurements and some mechanistic readouts, each answering a different question. None of the supplied evidence establishes that these interventions broadly reverse human aging or extend human lifespan.
Prevention makes exposure and representation decisive
A drug used to treat a defined disease can be judged against that disease’s risks and benefits. A preventive gerotherapeutic would be offered to people who may feel well, perhaps for years, to reduce the chance of several future problems. That changes the standard for acceptable side effects. An effect that is tolerable during a short course or in a high-risk population may not be acceptable as continuous treatment for otherwise healthy older adults.
Rapamycin shows the tension clearly. Its established clinical experience provides useful human pharmacology and safety information, but chronic mTOR suppression can carry metabolic and immune consequences. The review discusses intermittent or pulsed schedules as possible ways to preserve benefits while limiting unwanted exposure. Animal studies have encouraged these strategies, yet the optimal timing, dose and duration in humans remain unsettled. A proposed schedule is therefore a research design, not a general instruction for self-treatment.
Senolytics raise a different concern. Removing senescent cells may reduce harmful signaling, but the same cells can contribute to repair and tumor suppression. The heterogeneity of senescence makes broad clearance difficult, while off-target effects and tissue-specific differences complicate long-term prevention. Metformin has a comparatively extensive safety record, but that history does not automatically answer how it should be used for aging in people without diabetes; the review also notes a serious risk in people with significant renal impairment. Senomorphic agents such as some JAK inhibitors can carry infection and malignancy risks when used chronically at higher doses.
Trial design adds another layer of uncertainty. Older adults are often excluded from studies because comorbidities and polypharmacy make interpretation harder. Women, ethnic minorities and socioeconomically disadvantaged groups have also been underrepresented in many studies discussed by the review. A result from relatively healthy participants in high-income settings may not predict the balance of benefit and risk for people living with frailty, multiple medications or different baseline risks.
Researchers are also still working toward biological-age measures that respond to treatment and correspond to meaningful health outcomes. Epigenetic clocks, proteomic signatures and composite physiological indices are promising tools, but they do not yet provide a universally standardized basis for comparing every intervention. Short follow-up and disease-specific or surrogate endpoints make it difficult to know whether a measured change will persist, translate into function, or reduce the burden of several illnesses at once.
What drugs targeting aging could change for older adults
The future value of these therapies would be measured in ordinary human terms: more years in which older adults can move through daily life, maintain independence and spend less time managing several overlapping diseases. That possibility depends on a treatment producing durable clinical benefits, not merely changing a biomarker, and doing so with tolerable exposure across the diverse populations who might use it.
The September 2025 review shows why the field is moving toward mechanism-focused gerotherapeutics while still stopping short of a proven anti-aging prescription. Clearing senescent cells, quieting their signals and altering metabolic maintenance are distinct strategies with distinct trade-offs. Their eventual contribution may be substantial if clinical trials can connect those mechanisms to lasting function and safer prevention. Until then, the most honest interpretation is comparative rather than promotional: the science is testing several routes toward healthier later life, but durable gains in human healthspan remain to be demonstrated.
Key Sources
- Primary source: Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging Therapy.
DOI or Journal Page · Review or Meta-Analysis · 2025-09-25
Keep exploring